Company Overview

EDAP TMS S.A. is a France-based medical technology company specializing in minimally invasive therapeutic ultrasound technologies and robotic energy-based treatments for urology and other clinical applications. The company operates primarily in the healthcare technology and medical devices industries, with a focus on prostate disease treatment, particularly localized prostate cancer and benign prostatic hyperplasia (BPH). EDAP develops, manufactures, promotes, and distributes high-intensity focused ultrasound (HIFU) systems, extracorporeal shock wave lithotripsy (ESWL) devices, and associated consumables and services.

The company’s primary revenue drivers include sales and leasing of HIFU systems, recurring treatment-related revenue, maintenance contracts, disposables, and lithotripsy equipment sales. EDAP’s flagship HIFU platform, Focal One®, is positioned as a robotic image-guided solution designed for targeted prostate tissue ablation with reduced invasiveness compared with traditional surgical approaches. The company traces its origins to the late 1970s through the development of ultrasound and lithotripsy technologies in France and later expanded into therapeutic ultrasound applications. EDAP has evolved from a lithotripsy-focused company into a broader minimally invasive urology technology provider with growing emphasis on focal therapy and image-guided robotic treatment systems.

Business Operations

EDAP conducts operations through two principal business activities: the HIFU business and the Lithotripsy business. The HIFU segment includes development and commercialization of systems such as Focal One® and earlier-generation Ablatherm technologies used primarily for prostate cancer treatment. Revenue is generated through capital equipment sales, recurring consumable usage, treatment fees in certain markets, leasing arrangements, and service agreements. The Lithotripsy segment includes extracorporeal shock wave lithotripsy devices for urinary tract stone treatment, along with distribution of complementary urology products and maintenance services.

The company operates internationally through direct sales organizations and distributor networks across Europe, North America, Asia-Pacific, and selected emerging markets. EDAP maintains technology expertise in therapeutic ultrasound imaging integration, robotic treatment planning, and non-invasive energy delivery systems. The company has collaborated with hospitals, academic medical centers, and urology specialists to support clinical adoption and regulatory advancement of HIFU procedures. Public filings identify operational subsidiaries and commercial entities in several regions, including the United States, where EDAP has focused on expanding physician adoption following U.S. regulatory clearance for HIFU technologies.

Strategic Position & Investments

EDAP’s strategic direction centers on expanding adoption of focal therapy and image-guided minimally invasive treatments for prostate disease. The company has prioritized investment in the commercialization of Focal One®, physician training initiatives, clinical evidence generation, and reimbursement expansion. Management has emphasized growth through increased penetration of the U.S. urology market, where focal therapy remains an evolving treatment category supported by growing clinical utilization and patient demand for organ-sparing approaches.

The company has invested in software integration, imaging precision, and robotic treatment capabilities intended to differentiate its HIFU systems from traditional surgical and radiation-based approaches. EDAP has also pursued regulatory approvals and market access initiatives across multiple jurisdictions. While the company remains primarily focused on urology, management communications and investor materials have indicated continued evaluation of broader therapeutic ultrasound opportunities. Data regarding major acquisition activity is limited in public filings, and no large-scale transformative acquisitions were consistently identified across available verified public sources.

Geographic Footprint

EDAP is headquartered in Vaulx-en-Velin, France, and maintains commercial operations and distribution relationships across multiple international markets. The company has established a meaningful presence in Europe and the United States, with additional activity in parts of Asia-Pacific, the Middle East, and Latin America through distributors and regional partners. The United States has become an increasingly important market due to the commercialization potential of HIFU systems following regulatory authorization by the U.S. Food and Drug Administration.

The company’s technologies are installed in hospitals, cancer centers, and urology practices globally. EDAP’s international operational model combines direct commercial activities in selected strategic markets with third-party distribution networks in regions where localized medical device infrastructure and regulatory requirements vary. Public company disclosures indicate continued emphasis on expanding procedural adoption and installed base growth in developed healthcare systems with advanced urology treatment capabilities.

Leadership & Governance

EDAP’s governance structure reflects its position as a publicly traded medical technology company listed on Nasdaq. Leadership has consistently emphasized clinical innovation, physician engagement, minimally invasive treatment expansion, and disciplined commercialization strategy. The company’s management philosophy focuses on evidence-based adoption of therapeutic ultrasound technologies and long-term penetration of the prostate cancer treatment market.

Key executives include:

• Ryan Rhodes – Chief Executive Officer
• François Dietsch – Chief Financial Officer
• Marc Oczachowski – Chairman of the Board
• Philippe Chauveau – Chief Operating Officer
• Arnaud Dritsas – Chief Strategy Officer

Company leadership has publicly highlighted strategic priorities including expansion of the installed base for Focal One®, growth in recurring treatment revenue, physician education initiatives, and advancement of minimally invasive robotic ultrasound therapies. Executive information has been verified through public company filings, investor relations materials, and Nasdaq-listed corporate disclosures.